EML-VAC: Multivalent replicon vaccine against Ebola, Marburg and Lassa viruses

基于合成复制核糖核酸的多价出血热疫苗将提供从源头上阻止病毒爆发的最快和最具成本效益的方法之一。这比更传统的疫苗方法（如病毒载体和减毒病原体）具有显著优势，并且对于无法接种减毒活疫苗的个体（例如儿童和免疫功能低下者）更安全。我们的计划旨在开发一种多价疫苗，以预防最常见的人类病毒性出血热（埃博拉病毒、马尔堡病毒和拉沙热病毒）。靶点的选择是基于强有力的科学证据，即基于基因的方法可以防止临床前模型中的感染。该疫苗还可作为加强剂，与现有疫苗（如裂谷病毒vsv - ebov）联合使用。完全合成的制造和易于生产提供了在几周内生产数十万剂疫苗的潜力，针对不同出血性病毒的个别疫苗成分可以很容易地组合在一起。这可能对全球应对新出现的出血性病毒感染至关重要，因为无法可靠地预测下一次疫情的性质。在这方面，拟议的多价疫苗不仅有可能预防多种已知的出血性病毒，而且更有可能显示出对未来可能出现的新型变异的交叉保护。在该项目的第一部分（现已完成）中，我们成功地完成了将RNA平台从研究过程转移到完全建立可靠且经过验证的制造过程所需的繁重工作，确认了所生产产品在临床前模型中的效力。在这个第二部分项目中，我们将生产临床级材料（GMP），在I期人体临床试验中对疫苗进行必要的临床前毒理学和早期评估，以评估我们的泛出血热疫苗的安全性和免疫原性。我们有能力在两年的拨款期内完成从生产到首次人体临床试验所需的积极时间表，这是唯一可能的，因为我们的制造过程的稳健性和速度，以及组装团队在将疫苗概念从实验室转化为临床方面的独特能力。我们的最终愿景是利用我们的疫苗平台确保英国为任何最终的大流行做好准备，并在任何爆发情况下向全球提供疫苗。我们的方法将确保为低收入和中等收入国家提供适当的成本，并随时可供关注全球卫生的组织（例如无国界医生组织和世卫组织）使用：这些组织历来是最先发现和/或应对疫情的，因此处于协助实施任何疫苗接种战略的理想位置。我们的目标产品（TPP）是一种稳定的多价疫苗，在所有人群中接种一两次免疫后，可引发针对最常见的人类病毒性出血热的保护性免疫，在缺乏抗媒介免疫的情况下具有增强的潜力，并且可以以低成本快速生产。

A multivalent haemorrhagic fever vaccine based on synthetic replicating ribonucleic acid would provide one of the fastest and most cost-effective approaches to stop viral outbreaks at their source. This affords significant advantages over more conventional vaccine approaches such as viral vectors, and attenuated pathogens and would be safer in individuals unable to receive live attenuated vaccines (e.g. children and the immunocompromised ). Our program aims to develop a multivalent vaccine against the most common human viral haemorrhagic fevers ( Ebola, Marburg and Lassa fever virus). The choice of targets is based on strong scientific evidence that gene-based approaches can protect against infection in preclinical models. This vaccine may also find utility as a booster that can be used in combination with existing vaccines (e.g. rVSV-EBOV). The fully synthetic manufacture and ease of production provides the potential to produce hundreds of thousands of doses within a matter of weeks where the individual vaccine components targeting different haemorrhagic viruses can easily be combined. This may be critical to the global response against emerging haemorrhagic viral infections, as the nature of the next outbreak cannot be reliably predicted. In this respect the proposed multivalent vaccine has potential not only to protect against multiple known haemorrhagic viruses but is also more likely to show cross-protection against novel variants that may arise in the future. In Part 1 of this project (now complete) we successfully completed the heavy lifting required to move our RNA platform from a research process through to fully established robust and validated manufacturing process, confirming the potency of the produced product in preclinical models. In this Part 2 project we will manufacture clinical grade material (GMP), conduct the required preclinical toxicology and early evaluation of the vaccine in a phase I human clinical trial designed to assess the safety and immunogenicity of our pan-haemorrhagic fever vaccine. Our ability to deliver on the aggressive timelines required to move from manufacture through to completion of a first in human clinical trial within two-year grant funding period is only possible due to the robustness and speed of our manufacturing process and the unique competency of the assembled team in translating vaccine concepts from the bench to the bedside . Ultimately our vision is to use our vaccine platform to ensure UK preparedness for any eventual pandemic and to make vaccines globally available in the event of any outbreak situation. Our approach will ensure appropriate costing for low and middle-income countries and be readily available to organizations focused on global health (e.g. MSF and WHO): these groups have historically been the first to detect, and/or respond to an outbreak, and are therefore ideally positioned to assist in implementing any vaccination strategy. Our Target Product Profile (TPP) is a stable multivalent vaccine that can elicit protective immunity against the most common human viral haemorrhagic fevers following one or two immunisation across all populations, has potential for boosting in the absence of anti-vector immunity, and can be rapidly manufactured at low cost.